Parallel imports, the importation of genuine, branded pharmaceutical products by a party other than the authorized importer or distributor are a recurring issue in pharmaceutical trade. The product is authentic and originates with the rights holder, but it has been sourced from a different market and brought into the country outside official distribution channels. In some sectors and jurisdictions, parallel imports are tolerated or even encouraged as a means of price competition; in pharmaceuticals, and particularly in Iraq, the regulatory position is considerably more restrictive.
Why the Iraqi Position is Restrictive?
The starting point under Iraqi law is the regulated nature of the pharmaceutical import system. Importation of medicines is restricted to specific authorized parties: licensed scientific offices acting for the manufacturer, licensed drugstores with import endorsement, KIMADIA for public sector procurement, and certain institutions for direct use under special authorization. Anyone outside these categories acts unlawfully if they import medicines, regardless of whether the product itself is genuine. The structure of the system is designed to ensure traceability and accountability throughout the supply chain, and parallel imports inherently undermine those objectives.
Each registered product is associated with a specific licensed importer or distribution arrangement, recorded in the marketing authorization and known to the Ministry of Health. Import permits for specific consignments are issued only to authorized importers and only for products with valid registrations. A third party that obtains genuine product abroad; perhaps at a lower price generally lacks the licensing infrastructure to bring it through legal channels, and importation outside the authorized routes is a regulatory and customs offense, not merely a contractual breach.
Intellectual Property Dimensions
Intellectual property law adds another layer. Trademark rights, registered with the Iraqi Trademark Office, are enforceable against unauthorized importers under the Trademarks Law No. 21 of 1957 (as amended). The doctrine of exhaustion of rights; the principle that a rights holder cannot control further distribution of a product after it has been sold with consent applies in Iraq in a restricted manner, and the precise position on international exhaustion remains an evolving area. Patent rights, where applicable, may also be infringed by unauthorized importation of patented products, subject to similar exhaustion considerations. The cross-border application of these principles depends on the facts of each case and on the interpretation that Iraqi courts give to international exhaustion.
Public Health Considerations
Beyond IP and licensing, public health considerations weigh heavily against parallel imports of medicines. Iraq’s regulatory system depends on authorized supply chains with traceability, verifiable batch history, controlled storage conditions, and documented distribution. Parallel imports disrupt this traceability and create uncertainty about cold chain integrity, expiry management, and authenticity features. Recalls and pharmacovigilance become more difficult to execute when the product is in the market through channels the manufacturer does not control. The counterfeit risk is intertwined: when products move outside official channels, the risk of substitution with counterfeit, adulterated, or substandard product rises, and the difficulty of detecting that substitution rises with it.
Enforcement
Enforcement against parallel imports in Iraq combines several mechanisms. Customs authorities can detain consignments on documentation discrepancies, unauthorized importer status, and rights holder complaints. The Ministry of Health can seize parallel-imported product in the market, impose administrative penalties, and refer matters for criminal prosecution where appropriate. Rights holders can bring civil actions for trademark infringement, unfair competition, and breach of distribution arrangements. The effectiveness of enforcement depends on coordination across these layers, and on the quality of evidence the rights holder is able to provide.
Practical Scenarios
Parallel imports become relevant in several practical scenarios: shortages of officially imported products, price differentials between Iraq and neighboring markets, individual patient importation for personal use, and supply for specific clinical needs. Personal-use importation by patients, particularly for chronic conditions where the product is not available locally, occupies a distinct space and is sometimes addressed through case-by-case authorizations rather than treated as a regulatory offense. The line between legitimate compassionate import and commercial parallel trade is one the regulator draws in practice, and it is not always crisp.
Manufacturer Responses
Manufacturers can reduce parallel import incidence through commercial as well as legal measures. Consistent global pricing strategies that account for regional realities, careful selection and management of authorized distributors, robust anti-counterfeiting measures including serialization and tamper-evident packaging, market surveillance to detect parallel-imported product, and prompt enforcement action when parallel imports are identified all play a role. Manufacturers operating in multiple regional markets should coordinate their strategies regionally, because parallel imports into Iraq often originate from neighboring markets, and a policy that addresses Iraq in isolation tends to miss the underlying dynamic.
Risks for Downstream Operators
For distributors and pharmacies operating in Iraq, the practical message is clear. Sourcing medicines from anyone other than authorized suppliers exposes the buyer to license suspension, fines, and criminal prosecution, as well as civil liability for patient harm and reputational damage. The cost of unwittingly handling parallel-imported product can far exceed the price advantage that originally made it attractive. Documentation of the chain of custody and verification of supplier licenses are essential, and supply contracts should require suppliers to warrant the legitimacy of their supply chain.
Geopolitical Context
Iraq’s location at the crossroads of major pharmaceutical markets creates particular incentives for parallel and informal trade. Regional supply pressures, currency dynamics, and cross-border trafficking networks all play a role, and the line between parallel import and outright smuggling can be blurred in practice. The regulator’s attention to this area has been increasing, and we expect this trend to continue as electronic traceability systems develop and as customs cooperation across the region deepens.
How We Can Help
Etihad Law Firm advises pharmaceutical manufacturers, authorized importers, and other stakeholders on the legal and commercial aspects of parallel imports in Iraq. We assist with regulatory enforcement, customs interdiction, trademark and patent infringement actions, distribution agreement design, and broader supply chain integrity programs.